Close Menu

NEW YORK (GenomeWeb) — Lucence Diagnostics has partnered with Singapore Diagnostics to distribute its line of blood-based cancer diagnosis and screening tests in the Philippines, the companies announced today.

Lucence's tests are based on its patented sequencing technology and are designed to detect DNA fragments shed by a tumor into the blood.The tests target the most common cancers in Asia such as breast, colon, lung and nasopharyngeal cancer.

Additional terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.